Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Crohn disease

Crohn disease

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Crohn disease

49 trials tracked for Crohn disease: 16 in phase 3 or 4 and 10 with published results. The most-cited published study has 301 citations.

49Trials tracked
16Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 5 Phase 3 11 Phase 2 10 Phase 1 1 Other / NA 22
  1. Phase 3 Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year Completed · 301 cited
  2. Phase 3 Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab Completed · 127 cited
  3. Phase 4 Triple Combination Therapy in High Risk Crohn's Disease (CD) Completed · 92 cited
  4. Phase 3 A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease Completed · 91 cited
  5. Phase 3 BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Completed · 43 cited
  6. Phase 3 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Completed · 30 cited
Show 43 more trials
  1. Phase 4 Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Completed · 26 cited
  2. Phase 3 A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease Completed · 14 cited
  3. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 4 cited
  4. Phase 3 Loss of RESponse to Ustekinumab Treated by Dose Escalation Completed · 1 cited
  5. Phase 4 Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas Completed
  6. Phase 4 A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Completed
  7. Phase 3 Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease Completed
  8. Phase 3 Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC Completed
  9. Phase 3 Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease Completed
  10. Phase 3 A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease Completed
  11. Phase 2 A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease Completed
  12. Phase 2 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis Completed
  13. Phase 2 A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease Completed
  14. Phase 2 A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis Completed
  15. Phase 2 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease Completed
  16. Phase 2 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease Completed
  17. Phase 2 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease Completed
  18. Phase 2 A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) Completed
  19. Phase 2 Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease Completed
  20. Phase 2 Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease. Completed
  21. Phase 1 A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants Completed
  22. N/A National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life Completed
  23. N/A Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders Completed
  24. N/A Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143) Completed
  25. N/A Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease. Completed
  26. N/A Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease Completed
  27. N/A A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) Completed
  28. N/A A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD) Completed
  29. N/A Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes Completed
  30. N/A Digital Behavioral Interventions in Inflammatory Bowel Disease Completed
  31. N/A A Study of the Quality of Life in Adults With Crohn's Disease With Complex Perianal Fistulas Completed
  32. N/A Autoimmune Protocol Diet and Inflammatory Bowel Disease Completed
  33. N/A MRE as a Screening Tool for axSpA in IBD Completed
  34. N/A A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients Completed
  35. N/A The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study Completed
  36. N/A The Effect of Riboflavin in Crohn's Disease Completed
  37. N/A Crohn Disease Exclusion Diet After Single Medication De-escalation Completed
  38. N/A Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease Completed
  39. N/A A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants Completed
  40. N/A A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice Completed
  41. N/A Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease Completed
  42. N/A A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis Completed
  43. N/A Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Crohn disease: what the trials found

Several biologics have demonstrated efficacy in Crohn disease. Vedolizumab showed clinical response rates of 72.9% at week 14, 70.8% at week 30, and 68.8% at week 46 5. In a separate study, Vedolizumab achieved endoscopic remission in 34.5% of participants and endoscopic healing in 43.6% of participants at week 26 2.

Ustekinumab showed varying results across trials. One study reported clinical response rates of 49.1% and 37.4% at week 16 12, while another reported endoscopic response rates of 37.9% and 29.9% at week 48 8. A placebo-controlled trial for Ustekinumab showed clinical response rates of 66.2% and 72.3% at week 52 7. A separate study of Ustekinumab showed no significant difference in steroid-free clinical remission or endoscopic remission at week 48 1.

Other established treatments include infliximab, which showed significantly higher rates of corticosteroid-free clinical remission (up to 72.2%) and mucosal healing (up to 43.9%) in a multi-arm study 16. Certolizumab pegol showed clinical response in 40.5% and 34.0% of patients at week 6 15. BI 695501 demonstrated high clinical response rates at week 4 (88.0% and 93.1%) and week 24 (87.4% and 87.4%) 10.

Ozanimod showed no significant difference in CDAI scores, abdominal pain/stool frequency remission, or SES-CD score decreases compared to its comparator 11. Etrolizumab showed varying clinical remission rates at week 14 across different cohorts 9. In a study of RHB-104, patients on the combination showed a significantly shorter duration of time in remission compared to the comparator 13.

Recent results — preliminary, needs further review

  • TEV-48574 showed an endoscopic response in 16 and 18 participants in a study of moderate to severe Crohn disease 17.

For the clinician treating this condition

  • Vedolizumab is associated with consistent clinical response rates in Crohn disease patients over a 46-week period 5.
  • Infliximab demonstrates statistically significant improvements in mucosal healing and corticosteroid-free remission 16.
  • Ustekinumab shows evidence of clinical response and endoscopic response across multiple trials, though specific outcomes varied by study [1, 8, 12].
  • BI 695501 showed high rates of clinical response at both 4 and 24 weeks 10.

AI synthesis of 13 cited trials, updated Sep 3, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Crohn disease and ulcerative colitis causally raise ankylosing spondylitis risk
Rheumatology Meta-analysis
Crohn disease and ulcerative colitis causally raise ankylosing spondylitis risk Crohn's disease and ulcerative colitis linked to joint inflammation
This Mendelian randomization meta-analysis found positive causal relationships between Crohn disease and ulcerative colitis and ankylosing s…
People with Crohn's disease or ulcerative colitis face a higher risk of developing ankylosing spondylitis, a form of inflammatory joint dise…
NEJM Aug 3, 2026